Abstract
The aim of this study was to evaluate the usefulness of a major secretory protein of human chondrocytes (chondrex) as a potential serum marker of bone responsiveness to growth hormone (GH). The study included 18 children (10 F, 8 M), aged 10.9 ± 2.3 years, bone age 8.8 ± 2.7 years, height -2.3 ± 0.22 SDS, affected by isolated idiopathic GH deficiency (GHD). Serum samples for evaluation of chondrex, total, and bone alkaline phosphatase were taken before and 3 and 6 months following treatment with rhGH. The basal serum level of chondrex did not differ between patients (37 ± 22 ng/ml) and controls (33 ± 9.8 ng/ml). Following 6 months of treatment with rhGH, a significant increase of height velocity SDS (from -2.8 ± 0.5 to 1.3 ± 0.7), total (from 195 ± 47 to 264 ± 79 U/liter) and bone alkaline phosphatase (from 81 ± 21 to 108 ± 30 U/liter) was observed, while chondrex serum level remained unchanged (from 37 ± 22 to 36 ± 29 ng/ml). It was concluded that chondrex cannot be considered a reliable marker of bone responsiveness to GH in the growing child.
| Original language | English |
|---|---|
| Pages (from-to) | 45-46 |
| Number of pages | 2 |
| Journal | Calcified Tissue International |
| Volume | 67 |
| Issue number | 1 |
| Publication status | Published - 2000 |
Fingerprint
Keywords
- Chondrex
- Growth
- Growth hormone
- XKL-40
ASJC Scopus subject areas
- Endocrinology
Cite this
Influence of growth hormone on a new marker of cartilage metabolism (Chondrex). / Radetti, G.; Bozzola, M.; Braga, V.; Paganini, C.; Moretti, C.; Adami, S.
In: Calcified Tissue International, Vol. 67, No. 1, 2000, p. 45-46.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Influence of growth hormone on a new marker of cartilage metabolism (Chondrex)
AU - Radetti, G.
AU - Bozzola, M.
AU - Braga, V.
AU - Paganini, C.
AU - Moretti, C.
AU - Adami, S.
PY - 2000
Y1 - 2000
N2 - The aim of this study was to evaluate the usefulness of a major secretory protein of human chondrocytes (chondrex) as a potential serum marker of bone responsiveness to growth hormone (GH). The study included 18 children (10 F, 8 M), aged 10.9 ± 2.3 years, bone age 8.8 ± 2.7 years, height -2.3 ± 0.22 SDS, affected by isolated idiopathic GH deficiency (GHD). Serum samples for evaluation of chondrex, total, and bone alkaline phosphatase were taken before and 3 and 6 months following treatment with rhGH. The basal serum level of chondrex did not differ between patients (37 ± 22 ng/ml) and controls (33 ± 9.8 ng/ml). Following 6 months of treatment with rhGH, a significant increase of height velocity SDS (from -2.8 ± 0.5 to 1.3 ± 0.7), total (from 195 ± 47 to 264 ± 79 U/liter) and bone alkaline phosphatase (from 81 ± 21 to 108 ± 30 U/liter) was observed, while chondrex serum level remained unchanged (from 37 ± 22 to 36 ± 29 ng/ml). It was concluded that chondrex cannot be considered a reliable marker of bone responsiveness to GH in the growing child.
AB - The aim of this study was to evaluate the usefulness of a major secretory protein of human chondrocytes (chondrex) as a potential serum marker of bone responsiveness to growth hormone (GH). The study included 18 children (10 F, 8 M), aged 10.9 ± 2.3 years, bone age 8.8 ± 2.7 years, height -2.3 ± 0.22 SDS, affected by isolated idiopathic GH deficiency (GHD). Serum samples for evaluation of chondrex, total, and bone alkaline phosphatase were taken before and 3 and 6 months following treatment with rhGH. The basal serum level of chondrex did not differ between patients (37 ± 22 ng/ml) and controls (33 ± 9.8 ng/ml). Following 6 months of treatment with rhGH, a significant increase of height velocity SDS (from -2.8 ± 0.5 to 1.3 ± 0.7), total (from 195 ± 47 to 264 ± 79 U/liter) and bone alkaline phosphatase (from 81 ± 21 to 108 ± 30 U/liter) was observed, while chondrex serum level remained unchanged (from 37 ± 22 to 36 ± 29 ng/ml). It was concluded that chondrex cannot be considered a reliable marker of bone responsiveness to GH in the growing child.
KW - Chondrex
KW - Growth
KW - Growth hormone
KW - XKL-40
UR - http://www.scopus.com/inward/record.url?scp=0033941291&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0033941291&partnerID=8YFLogxK
M3 - Article
C2 - 10908412
AN - SCOPUS:0033941291
VL - 67
SP - 45
EP - 46
JO - Calcified Tissue International
JF - Calcified Tissue International
SN - 0171-967X
IS - 1
ER -